Literature DB >> 24210678

Renal artery calcium, cardiovascular risk factors, and indexes of renal function.

Daniel A Roseman1, Shih-Jen Hwang2, Emily S Manders3, Christopher J O'Donnell4, Ashish Upadhyay1, Udo Hoffmann5, Caroline S Fox6.   

Abstract

Vascular calcium is well studied in the coronary and peripheral arteries, although there are limited data focusing on calcium deposits specific to renal arteries. The associations among renal artery calcium (RAC), cardiovascular disease risk factors, and indexes of renal function are unknown. We examined 2,699 Framingham Heart Study participants who were part of a multidetector computed tomography substudy from 2008 to 2011. RAC was measured as a calcified plaque of >130 HU and an area of >3 contiguous pixels. Detectable RAC was defined as an Agatston score >0. Chronic kidney disease was defined as an estimated glomerular filtration rate of <60 ml/min/1.73 m(2). Microalbuminuria was defined as an albumin/creatinine ratio of ≥17 mg/g for men and ≥25 mg/g for women. Multivariable adjusted logistic regression models were used to evaluate the associations between RAC, cardiovascular disease risk factors, and renal function. The associations were secondarily adjusted for coronary artery calcium (CAC) that was used as a marker of nonrenal systemic vascular calcium. The prevalence of RAC was 28.2%; this was similar in women (28.8%) and men (27.5%). Patients with RAC had a higher odds of microalbuminuria (odds ratio [OR] 1.79, 95% confidence interval [CI] 1.22 to 2.61, p = 0.003), hypertension (OR 2.11, 95% CI 1.69 to 2.64, p <0.001), and diabetes (OR 1.60, 95% CI 1.14 to 2.24, p = 0.01) but not chronic kidney disease (OR 0.87, 95% CI 0.58 to 1.32). After adjustment for CAC, the association with microalbuminuria and hypertension persisted, but the association with diabetes became nonsignificant. In conclusion, RAC is common and independently associated with microalbuminuria and hypertension after adjustment for nonrenal vascular calcium. RAC may be uniquely associated with these markers of renal end-organ damage. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24210678      PMCID: PMC3882167          DOI: 10.1016/j.amjcard.2013.09.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Increased aortic stiffness: an unfavorable cardiorenal connection.

Authors:  Gary F Mitchell
Journal:  Hypertension       Date:  2004-01-12       Impact factor: 10.190

2.  Prevalence and distribution of coronary artery calcification in asymptomatic British population.

Authors:  George Koulaouzidis; Paul J Jenkins; Tony McArthur
Journal:  Can J Cardiol       Date:  2012-11-10       Impact factor: 5.223

3.  Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men.

Authors:  R Pedrinelli; G Dell'Omo; G Penno; S Bandinelli; A Bertini; V Di Bello; M Mariani
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

4.  Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race.

Authors:  Holly J Mattix; Chi-Yuan Hsu; Shimon Shaykevich; Gary Curhan
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

5.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

6.  Renal artery calcified plaque associations with subclinical renal and cardiovascular disease.

Authors:  Barry I Freedman; Fang-Chi Hsu; Carl D Langefeld; Donald W Bowden; Shahriar Moossavi; Bonnie N Dryman; J Jeffrey Carr
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

Review 7.  Arterial stiffness and kidney function.

Authors:  Michel E Safar; Gérard M London; Gérard E Plante
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

Review 8.  The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.

Authors:  Ursula C Brewster; Mark A Perazella
Journal:  Am J Med       Date:  2004-02-15       Impact factor: 4.965

Review 9.  Vascular calcification: mechanisms and clinical ramifications.

Authors:  Moeen Abedin; Yin Tintut; Linda L Demer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-05-20       Impact factor: 8.311

10.  Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study.

Authors:  Katsuhiko Kohara; Yasuharu Tabara; Rieko Tachibana; Jun Nakura; Tetsuro Miki
Journal:  Hypertens Res       Date:  2004-07       Impact factor: 3.872

View more
  12 in total

1.  Relation Between Calcified Atherosclerosis in the Renal Arteries and Kidney Function (from the Multi-Ethnic Study of Atherosclerosis).

Authors:  Devesh Vashishtha; Robyn L McClelland; Joachim H Ix; Dena E Rifkin; Nancy Jenny; Matthew Allison
Journal:  Am J Cardiol       Date:  2017-07-24       Impact factor: 2.778

2.  Bi-directional analysis between fatty liver and cardiovascular disease risk factors.

Authors:  Jiantao Ma; Shih-Jen Hwang; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Raymond T Chung; Emelia J Benjamin; Daniel Levy; Caroline S Fox; Michelle T Long
Journal:  J Hepatol       Date:  2016-10-10       Impact factor: 25.083

3.  Impact of the explanting surgeon's impression of donor arteriosclerosis on outcome of kidney transplantations from donors aged ≥65 years.

Authors:  Fabian Echterdiek; Constantin Tilgener; Jürgen Dippon; Daniel Kitterer; Justus Scheder-Bieschin; Gregor Paul; Matthias Ott; Ulrich Humke; Vedat Schwenger; Joerg Latus
Journal:  Langenbecks Arch Surg       Date:  2021-11-26       Impact factor: 3.445

4.  Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study.

Authors:  William Y Park; Ioanna Yiannakou; Julie M Petersen; Udo Hoffmann; Jiantao Ma; Michelle T Long
Journal:  Clin Gastroenterol Hepatol       Date:  2021-11-06       Impact factor: 13.576

5.  Association of Soluble TNFR-1 Concentrations with Long-Term Decline in Kidney Function: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Pavan K Bhatraju; Leila R Zelnick; Michael Shlipak; Ronit Katz; Bryan Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2018-10-04       Impact factor: 10.121

6.  A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Jiantao Ma; Rohit Loomba; Raymond T Chung; Emelia J Benjamin
Journal:  Liver Int       Date:  2018-03-12       Impact factor: 5.828

7.  The association of renal artery calcification with hypertension in community-living individuals: the multiethnic study of atherosclerosis.

Authors:  Isac C Thomas; Amanda R Ratigan; Dena E Rifkin; Joachim H Ix; Michael H Criqui; Matthew J Budoff; Matthew A Allison
Journal:  J Am Soc Hypertens       Date:  2015-12-13

8.  Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis.

Authors:  Michelle T Long; Alison Pedley; Lisandro D Colantonio; Joseph M Massaro; Udo Hoffmann; Paul Muntner; Caroline S Fox
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-01       Impact factor: 11.382

9.  Hepatic steatosis is associated with lower levels of physical activity measured via accelerometry.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Dale W Esliger; Ramachandran S Vasan; Caroline S Fox; Joanne M Murabito
Journal:  Obesity (Silver Spring)       Date:  2015-05-09       Impact factor: 5.002

10.  The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Caroline S Fox
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.